No Data
Youniwai (301166.SZ): Net income is expected to decline by 70.24%-80.16% year-on-year in 2024.
Gelonghui reported on January 20 that Youningwei (301166.SZ) expects a net income of 8 million to -12 million yuan in 2024, a decrease of 70.24% to 80.16% compared to the same period last year, with a non-recurring loss of 13.24 million to -17.24 million yuan. 1. In 2024, affected by changes in downstream market demand, competition in the domestic life sciences service market has intensified further, pressuring the company's gross margin, and revenue did not meet expectations; focusing on the ultimate strategy for antibodies, the company continues to increase its R&D investment in its own products; during the reporting period, the over-raised funds invested in the project "Self-brand Product Production Base Project (
Unionway: 2024 performance forecast
Yuningwei (301166.SZ): has repurchased a total of 0.80% of its shares.
On January 2, Gelonghui announced that, as of December 31, 2024, the company had repurchased a total of 690,700 shares through a share buyback special Account via centralized bidding Trade, accounting for 0.80% of the company's total share capital, with the highest Fill Price being 31 yuan/share and the lowest Fill Price being 24.98 yuan/share, with a total payment amounting to 19.494546 million yuan (excluding transaction fees).
Yuningwei (301166.SZ) terminates the absorption merger of Nanjing Yuningwei with Nanjing Youai.
You Ningwei (301166.SZ) announced that Nanjing You Ningwei (a wholly-owned subsidiary of the company) originally planned to conduct a merger by absorption...
Shareholder Taili Investment and its concerted actions have completed a shareholding reduction of 1.36% in Youniwei (301166.SZ).
Unicore (301166.SZ) announced that the company's shareholder shanghai Entrepreneurship Relay Taili Entrepreneurship Investment Center (Limited Partnership)...
Unigroup Guoxin (301166.SZ): cumulative repurchased 0.49% of shares.
Grant Hui Nov. 1st | Yuninwei (301166.SZ) announced that as of October 31, 2024, the company repurchased a total of 421,700 shares of the company through a special securities account for share repurchases in a centralized auction trading manner, accounting for 0.49% of the total share capital of the company. The highest fill price was 30 yuan/share, and the lowest fill price was 24.98 yuan/share, with a total amount paid of 11,369,227 yuan (excluding transaction costs). The repurchase of shares this time is in compliance with relevant laws, administrative regulations, normative documents, and company share repurchase schemes.
Shanghai Universal BiotechLtd (SZSE:301166) Is Reinvesting At Lower Rates Of Return
